Headache frequency and intensity in female migraineurs using desogestrel-only contraception: A retrospective pilot diary study

Cephalalgia

Volumn 33, Issue 5, 2013, Pages 340-346

  Merki Feld, Gabriele S ^a   Imthurn, Bruno ^a   Langner, Ronald ^b   Sándor, Peter S ^a,c   Gantenbein, Andreas R ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b KLINIK HIRSLANDEN   (Switzerland)

^c Neurorehabilitation RehaClinic Baden and Bad Zurzach ^*  (Switzerland)

Author keywords

cardiovascular risk; contraception; desogestrel only pill; headache; Hormonal migraine; migraine with aura; migraine without aura

Indexed keywords

DESOGESTREL; GESTAGEN; TRIPTAN DERIVATIVE;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; PILOT STUDY; RETROSPECTIVE STUDY;

ADULT; CONTRACEPTIVES, ORAL, SYNTHETIC; DESOGESTREL; FEMALE; HEADACHE; HUMANS; MEDICAL RECORDS; PILOT PROJECTS; RETROSPECTIVE STUDIES;

EID: 84875458754     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102412473373     Document Type: Article

References (36)

1. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: Case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ. 1999 ; 318: 13-18
2. Bigal ME, Kurth T, Santanello N, et al. Migraine and cardiovascular disease: A population-based study. Neurology. 2010 ; 74: 628-635
3. Tzourio C, Tehindrazanarivelo A, Iglesias S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ. 1995 ; 310: 830-833
4. Schurks M, Buring JE, Kurth T. Migraine, migraine features, and cardiovascular disease. Headache. 2010 ; 50: 1031-1040
5. Tzourio C, Iglesias S, Hubert JB, et al. Migraine and risk of ischaemic stroke: A case-control study. BMJ. 1993 ; 307: 289-292
6. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA. 2000 ; 284: 72-78
7. Sacco S, Ricci S, Degan D, et al. Migraine in women: The role of hormones and their impact on vascular diseases. J Headache Pain. 2012 ; 13: 177-189
8. Lidegaard Ø, Løkkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: National follow-up study. BMJ. 2009 ; 339: b2890 - b2890
9. Aegidius K, Zwart JA, Hagen K, et al. Oral contraceptives and increased headache prevalence: The Head-HUNT Study. Neurology. 2006 ; 66: 349-353
10. Allais G, Gabellari IC, Airola G, et al. Headache induced by the use of combined oral contraceptives. Neurol Sci. 2009 ; 30 (Suppl. 1). S15 - S17
11. Teepker M, Peters M, Kundermann B, et al. The effects of oral contraceptives on detection and pain thresholds as well as headache intensity during menstrual cycle in migraine. Headache. 2011 ; 51: 92-104
12. Loder EW, Buse DC, Golub JR. Headache as a side effect of combination estrogen-progestin oral contraceptives: A systematic review. Am J Obstet Gynecol. 2005 ; 193: 636-649
13. Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results. Contraception. 2006 ; 74: 439-445
14. Macgregor EA. Menstrual migraine: A clinical review. J Fam Plann Reprod Health Care. 2007 ; 33: 36-47
15. Macgregor EA, Rosenberg JD, Kurth T. Sex-related differences in epidemiological and clinic-based headache studies. Headache. 2011 ; 51: 843-859
16. Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception. 2001 ; 64: 295-299
17. Kivela A, Ruuskanen M, Agren U, et al. The effects of two progrestogen-only pills containing either desogestrel (75 microgram/day) or levonorgestrel (30 microgram/day) on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care. 2001 ; 6: 71-77
18. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24(Suppl 1): 9-160.
19. Somerville B. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972 ; 22: 355-365
20. Martin VT, Behbehani M. Ovarian hormones and migraine headache: Understanding mechanisms and pathogenesis - part I. Headache. 2006 ; 46: 3-23
21. Jung-Hoffmann C, Fitzner M, Kuhl H. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: Pharmacokinetics and pharmacodynamic parameters. Horm Res. 1991 ; 36: 238-246
22. Prange-Kiel J, Rune GM, Zwirner M, et al. Regulation of estrogen receptor alpha and progesterone receptor (isoform A and B) expression in cultured human endometrial cells. Exp Clin Endocrinol Diabetes. 2001 ; 109: 231-237
23. Casper RF. Regulation of estrogen/progestogen receptors in the endometrium. Int J Fertil Menopausal Stud. 1996 ; 41: 16-21
24. Aguirre C, Jayaraman A, Pike C, et al. Progesterone inhibits estrogen-mediated neuroprotection against excitotoxicity by down-regulating estrogen receptor-beta. J Neurochem. 2010 ; 115: 1277-1287
25. Jayaraman A, Pike CJ. Progesterone attenuates oestrogen neuroprotection via downregulation of oestrogen receptor expression in cultured neurones. J Neuroendocrinol. 2009 ; 21: 77-81
26. Finocchi C, Ferrari M. Female reproductive steroids and neuronal excitability. Neurol Sci. 2011 ; 32 (Suppl 1). S31 - S35
27. Nappi RE, Sances G, Allais G, et al. Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: A prospective diary-based pilot study. Contraception. 2011 ; 83: 223-228
28. Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Venous thrombosis in users of non-oral hormonal contraception: Follow-up study, Denmark 2001-10. BMJ. 2012 ; 344: e2990 - e2990
29. MacGregor EA, Guillebaud J. Combined oral contraceptives, migraine and ischaemic stroke. Clinical and Scientific Committee of the Faculty of Family Planning and Reproductive Health Care and the Family Planning Association. Br J Fam Plann. 1998 ; 24: 55-60
30. Joshi G, Pradhan S, Mittal B. Role of the oestrogen receptor (ESR1 PvuII and ESR1 325 C->G) and progesterone receptor (PROGINS) polymorphisms in genetic susceptibility to migraine in a North Indian population. Cephalalgia. 2010 ; 30: 311-320
31. Calhoun A, Ford S, Pruitt A. The impact of extended-cycle vaginal ring contraception on migraine aura: A retrospective case series. Headache. 2012 ; 52: 1246-1253
32. De Leo V, Scolaro V, Musacchio MC, et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril. 2011 ; 96: 917-920
33. Sulak P, Willis S, Kuehl T, et al. Headaches and oral contraceptives: Impact of eliminating the standard 7-day placebo interval. Headache. 2007 ; 47: 27-37
34. Neue Studien zum Risiko von Venenthrombosen und lungenembolien unter hormonalen Verhütungsmutteln - Empfehlungen Swissmedic 5.12.2011 (2011).
35. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: Case-control study using United States claims data. BMJ. 2011 ; 342: d2151 - d2151
36. Wiegratz I, Kissler S, Kuhl H, et al. Extended and continuous use of hormonal contraceptives to reduce menstruation. Womens Health (Lond Engl). 2006 ; 2: 705-716